MS drug Tysabri should return to market-US panel
Wed, 08 Mar 2006 10:27 PM EST
... GAITHERSBURG, Maryland (Reuters) - A panel of independent experts on Wednesday unanimously urged the U.S. return of Biogen Idec''s multiple sclerosis drug Tysabri, a medicine abruptly pulled from the market last year after it was linked to a life-threatening side effect. ...
Related Topics
- Tysabri
- Multiple Sclerosis
- Liver Panel
- Morphine ER
- Research
- Interferon Beta-1a Injection (Avonex
- Glatiramer Injection
- Rofecoxib Oral Suspension
- Drug Safety
- Prescription Drugs
- Multiple Sclerosis/ms
- Cerivastatin - Withdrawn From The Market
- Drug Side Effects
- Docusate
- Drug Abuse
- Drug Information
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Tragacanth
- Naltrexone

Not Signed In -


